OBI Pharma (ROCO:4174) LT-Debt-to-Total-Asset: 0.10 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
43 GF Score
Price NT$29.45
GF Value NT$138.67
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma LT-Debt-to-Total-Asset?

OBI Pharma ROCO:4174 +3.70% 43 LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.67 (Possible Value Trap). The stock has 9 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OBI Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.10.

OBI Pharma's long-term debt to total assets ratio increased from Dec. 2024 (0.07) to Dec. 2025 (0.10). It may suggest that OBI Pharma is progressively becoming more dependent on debt to grow their business.

OBI Pharma  (ROCO:4174) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OBI Pharma LT-Debt-to-Total-Asset Related Terms

OBI Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OBI Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma LT-Debt-to-Total-Asset Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.08 0.07 0.10

OBI Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.08 0.09 0.10 0.10
ROCO:4174
43GF Score
OBI Pharma Inc ROCO:4174
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma LT-Debt-to-Total-Asset Calculation

OBI Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=339.437/3421.265
=0.10

OBI Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=339.437/3421.265
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.10 mean?
OBI Pharma (ROCO:4174) has a LT-Debt-to-Total-Asset of 0.10 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's LT-Debt-to-Total-Asset too high?
OBI Pharma's current LT-Debt-to-Total-Asset is 0.10. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?
OBI Pharma's LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OBI Pharma and its competitors. OBI Pharma's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.67, compared to a current price of NT$29.45 — trading 78.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$29.45 is trading 78.8% below its estimated GF Value™ of NT$138.67. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • LT-Debt-to-Total-Asset: 0.10
  • GF Value™: NT$138.67 vs. price of NT$29.45 (78.8% below fair value)
  • GF Score™: 43/100 with 9 warning signs

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score

Get the complete analysis for ROCO:4174

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.45
Price
NT$138.67
GF Value